Puma | The Independent
The latest breaking news, comment and features from The Independent.
www.independent.co.ukI don’t have live access to current news in this turn. Here’s what I can tell you based on the latest available public summaries up to my last update, and I can dig deeper if you want me to search again:
-
Puma Biotechnology (Puma) focus: Neratinib (NERLYNX) and alisertib (ALISCA) programs, with ongoing clinical updates and geographic licensing for NERLYNX outside the U.S. [source summaries indicate ongoing commercialization efforts and multiple trial updates through 2025–2026]. I can pull the most recent press releases if you’d like a precise timeline and quotes.[1]
-
Recent financial/performance signals: Puma reported profitability milestones in 2025 with guidance suggesting continued profitability in 2026, alongside advancing ALISCA trials in breast and lung cancer settings. If you want, I can fetch the exact quarterly figures and milestones from their 2025 annual/quarterly reports.[1]
-
Related corporate activity: No clear evidence in the provided results of a separate “Project Puma” initiative outside Puma Biotechnology’s existing clinical programs; the other “Puma” hits in other companies (e.g., Puma Exploration) are unrelated to Puma Biotechnology’s operations. If you meant a different organization or a specific project with that codename, I can narrow the search to that entity.[2][3]
If you want the latest, I can perform a targeted web search now for “Project Puma” and filter to corporate, tech, or biotech contexts to pin down the exact entity and the newest developments. Would you like me to do that and provide a concise, sourced update with dates and key milestones?